FORM 4
☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

GILL SIMBA		 2. Issuer Name and Ticker or Trading Symbol

Evelo Biosciences, Inc. [ EVLO ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
President & CEO
(Last)          (First)          (Middle)

C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE		 3. Date of Earliest Transaction (MM/DD/YYYY)

6/8/2023
(Street)

CAMBRIDGE, MA 02139		 4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)        (State)        (Zip)
Rule 10b5-1(c) Transaction Indication
☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) $0.97 6/8/2023  A (1)  1000000     (2)3/16/2033 Common Stock 1000000 $0 1000000 D  
Explanation of Responses:
(1) Om March 17, 2023, the reporting person was granted an option to purchase 1,000,000 shares of the issuer's common stock subject to certain conditions, including the approval of the amendment and restatement of the Evelo Biosciences, Inc. 2018 Incentive Award Plan (the "2018 Plan") by stockholders at the issuer's 2023 Annual Meeting of Stockholders. The stockholders approved the amendment and restatement of the 2018 Plan on June 8, 2023.
(2) The option vests in forty-eight (48) substantially equal installments at the end of each monthly anniversary of February 7, 2023, subject to the reporting person's continued service to the issuer on each such vesting date.

Remarks:
Exhibit 24: Power of Attorney

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
GILL SIMBA
C/O EVELO BIOSCIENCES, INC.
620 MEMORIAL DRIVE
CAMBRIDGE, MA 02139		X
President & CEO
Signatures
/s/ Marella Thorell, Attorney-in-Fact for Balkrishan (Simba) Gill, Ph.D.6/12/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Evelo Biosciences (NASDAQ:EVLO)
Historical Stock Chart
From Feb 2025 to Mar 2025 Click Here for more Evelo Biosciences Charts.
Evelo Biosciences (NASDAQ:EVLO)
Historical Stock Chart
From Mar 2024 to Mar 2025 Click Here for more Evelo Biosciences Charts.